Therefore, lower plasma levels of IL-7 in COVID-19 patients imply another possible mechanism underlying lymphopenia in COVID-19 disease, which could be overcome by the therapeutic benefits of IL-7 therapy. This evidence concerns the gene IL7 and lymphopenia.